Search academic texts

Information × Registration Number 0225U000340, (0122U000576) , R & D reports Title To study the features of the pathogenesis of lung emphysema in the patients with bronchial asthma who have had a COVID-19 and to work out the technology for their treatment (clinical and experimental studies) popup.stage_title Вивчити особливості патогенезу емфіземи легень у перехворівших на COVID-19 хворих на бронхіальну астму та розробити технологію їх лікування (клініко-експериментальні дослідження) Head Feschenko Yurii I., Доктор медичних наукYashyna Liudmyla O., д.мед.н. Registration Date 09-01-2025 Organization State organization "National scientific center of phthisiatry, pulmonology and allergology named after F. G. Yanovskyi National academy of medical sciences of Ukraine" popup.description1 To increase the effectiveness of treatment of the patients with bronchial asthma who have had a COVID-19 taking into account the features of the pathogenesis of lung damage and clinical and functional characteristics popup.description2  Object – 272 patients (among them 165 patients with asthma and 107 patients with post-COVID-19 syndrome); 32 white laboratory rats. Aim – to increase the effectiveness of the treatment of bronchial asthma patients who have had COVID-19, taking into account the features of the pathogenesis of lung injury and clinical, functional characteristics. Methods – questionnaire, clinical, functional, radiological, laboratory, experimental, statistical. The clinical and functional characteristics of patients with bronchial asthma who have had COVID-19 are the uncontrolled asthma, obstructive-restrictive lung function disorders, decreased tolerance to physical activity. It was established that in experimental pulmonary emphysema the increased oxidative stress, violation of the of antioxidant system functions take place. It was founded that cytoflavin leads to the inhibition of the free radical oxidation and increasing of the antioxidant activity in experimental pulmonary emphysema. A diagnostic algorithm of respiratory muscle dysfunction in patients with bronchial asthma after COVID-19 at the primary medical care level has been developed, which has high sensitivity (89,8 %) and specificity (81,8 %) and allows to increase the accuracy of the diagnosis of respiratory muscle dysfunction by 18,3 %. An algorithm for optimizing basic therapy in asthma patients who have had COVID-19 has been developed, which allows to identify reactivation of EBV infection as the cause of uncontrolled asthma in 70,6 % of the patients and achieve clinical effectiveness in 88,3 % and functional effectiveness in 75,0 % of the patients. A technology for treatment of bronchial asthma patients who have had COVID-19 has been created, which allows to reduce bronchial obstruction by 15,9% and improve bronchial patency at the level of the middle bronchi by 11,7% according spirometry (FEV1 and MEF50) and to enhance tolerance to physical activity. Sphere of application – therapy, pulmonology, allergology. Product Description popup.authors Ihnatieva Victoriia I. Vlasova Nataliia A. Halai Liudmyla A. Humeniuk Halyna L Zvol Inna V. Korzhov Vitalii I. Kuryk Lesia M. Moskalenko Svitlana M. Opimakh Svitlana H. Parkhomenko Nataliia V. Polianska Maryna O. Prymushko Nataliia A. Feshchenko Yurii I. Chumak Iryna V. popup.nrat_date 2025-01-09 Close